Adverum Biotechnologies, Inc.
ADVM
$4.18
$0.010.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -72.22% | -72.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -72.22% | -72.22% |
| Cost of Revenue | 87.03% | 33.25% | -1.13% | -25.55% | -41.28% |
| Gross Profit | -90.95% | -31.78% | 2.52% | 23.28% | 39.88% |
| SG&A Expenses | 31.05% | 43.63% | 57.68% | 50.24% | 27.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.92% | 53.22% | 39.78% | 20.53% | -1.46% |
| Operating Income | -63.19% | -52.44% | -39.00% | -23.12% | -0.54% |
| Income Before Tax | -70.62% | -57.17% | -40.47% | -22.19% | 5.01% |
| Income Tax Expenses | -- | -- | -- | -- | -1,631.08% |
| Earnings from Continuing Operations | -72.25% | -58.64% | -41.75% | -23.26% | 5.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.25% | -58.64% | -41.75% | -23.26% | 5.96% |
| EBIT | -63.19% | -52.44% | -39.00% | -23.12% | -0.54% |
| EBITDA | -66.26% | -55.60% | -41.99% | -25.80% | -2.64% |
| EPS Basic | -26.97% | 1.79% | 24.93% | 37.61% | 40.33% |
| Normalized Basic EPS | -25.10% | 2.96% | 25.67% | 38.16% | 36.99% |
| EPS Diluted | -26.97% | 1.79% | 24.93% | 37.61% | 40.33% |
| Normalized Diluted EPS | -25.10% | 2.96% | 25.67% | 38.16% | 36.99% |
| Average Basic Shares Outstanding | 26.35% | 45.47% | 78.64% | 96.15% | 69.97% |
| Average Diluted Shares Outstanding | 26.35% | 45.47% | 78.64% | 96.15% | 69.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |